Ascentage Pharma Group International

Price & Volume

Stats

52W Range	$16.50-$48.45
Market Cap	$2.6B
Shares Short	254

Financials

Revenue (12 Mos)	$390.6M
Revenue Growth (YoY)	-71.6%
Gross Profit (12 Mos)	$354.9M
Diluted EPS	-$2.08

News

Yahoo Finance • last month

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

Yahoo Finance • last month

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

Yahoo Finance • last month

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

Yahoo Finance • last month

ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances

About

CEO	Dr. Dajun Yang M.D., Ph.D.
Address	Suzhou Industrial Park, Suzhou, China, 215000
Sector	Healthcare
Industry	Biotechnology
Full-Time Employees	605